- Report
- April 2026
- 120 Pages
Global
From €5606EUR$5,950USD£4,667GBP
- Report
- March 2026
- 120 Pages
Global
From €5606EUR$5,950USD£4,667GBP
- Report
- June 2026
- 296 Pages
Global
From €2355EUR$2,500USD£1,961GBP
- Report
- November 2026
- 235 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 224 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 374 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 419 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 578 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 577 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 380 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 172 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 372 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 488 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 184 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 382 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 360 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 163 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 262 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 174 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 392 Pages
Global
From €5512EUR$5,850USD£4,589GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more